Retained Earnings (Accumulated Deficit) of Universe Pharmaceuticals INC from 30 Sep 2020 to 30 Sep 2025
- Taxonomy & unit
- us-gaap: USD
- Description
- The cumulative amount of the reporting entity's undistributed earnings or deficit.
- Summary
-
Universe Pharmaceuticals INC quarterly Retained Earnings (Accumulated Deficit) in USD history and change rate from 30 Sep 2020 to 30 Sep 2025.
- Universe Pharmaceuticals INC Retained Earnings (Accumulated Deficit) for the quarter ending 30 Sep 2025 was $13,843,623.
- Source SEC data
- View on sec.gov
Retained Earnings (Accumulated Deficit), Quarterly (USD)
Retained Earnings (Accumulated Deficit), YoY Quarterly Change (%)
Universe Pharmaceuticals INC Quarterly Retained Earnings (Accumulated Deficit) (USD)
| Period | Value | YoY Chg | Change % | Date | Report | Filed | Fiscal Year | Fiscal Period |
|---|---|---|---|---|---|---|---|---|
| Q3 2025 | $13,843,623 | +$10,157,724,377 | 30 Sep 2025 | 20-F | 29 Jan 2026 | 2025 | FY | |
| Q3 2024 | $10,171,568,000* | -$10,170,123,730 | 30 Sep 2024 | 20-F | 29 Jan 2026 | 2025 | FY | |
| Q1 2024 | $2,942,153 | -$18,549,091 | -119% | 31 Mar 2024 | 6-K | 20 Sep 2024 | 2024 | Q2 |
| Q3 2023 | $1,444,270 | -$17,766,635 | -109% | 30 Sep 2023 | 20-F | 29 Apr 2025 | 2024 | FY |
| Q1 2023 | $15,606,938 | -$11,183,728 | -42% | 31 Mar 2023 | 6-K | 31 Aug 2023 | 2023 | Q2 |
| Q3 2022 | $16,322,365 | -$8,736,566 | -35% | 30 Sep 2022 | 20-F | 30 Jan 2024 | 2023 | FY |
| Q1 2022 | $26,790,666 | 31 Mar 2022 | 6-K | 16 Aug 2022 | ||||
| Q3 2021 | $25,058,931 | +$11,319,952 | +82% | 30 Sep 2021 | 20-F | 10 Feb 2023 | 2022 | FY |
| Q3 2020 | $13,738,979 | 30 Sep 2020 | 20-F | 31 Jan 2022 | 2021 | FY |
* An asterisk sign (*) next to the value indicates that the value is likely invalid.